Novick D, Montgomery W, Brnabic A, Aguado J, Kadziola Z, Peng X, Brugnoli R, Haro JM. Prognostic implications of somatic symptoms in patients with depression. Results from a three-month, prospective, observational study from Asia. Poster presented at the 28th CINP World Congress of Neuropsychopharmacology; June 3, 2012. Stockholm, Sweden. [abstract] Int J Neuropsychopharmacol. 2012 Jun; 15(1):191. doi: 10.1017/S1461145712000508
Eap CB, Vandenberghe F, Choong E, Saigi-Morgui N, Ambresin AE, von Gunten A, Conus P. Clinical and pharmacogenetic study on psychotropic drug induced weight gain and other metabolic complications in a Swiss psychiatric population. Poster presented at the 2012 World Congress of the International College of Neuropsychopharmacology; June 2012. Stockholm, Sweden. [abstract] Int J Neuropsychopharmacol. 2012 Jun 1; 15(Suppl 1):101. doi: 10.1017/S1461145712000508
Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA. Toward development of a fibromyalgia responder index and disease activity score: oMERACT module update. J Rheumatol. 2011 Jul 1;38(7):1487-95.
Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct 1;36(10):2330-4.
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009 Oct 1;36(10):2318-29.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA. OMERACT 8 workshop: fibromyalgia syndrome. J Rheumatol. 2007 Jun;34(6):1415-25.
Williams VS, Feltner D, Hill C, Morlock R. Evaluation of a global anxiety – Visual analog scale (ga-vas) in a clinical trial comparing lorazepam and paroxetine in patients with gad. Poster presented at the CINP 25th Biennial Congress; July 2006. [abstract] Int J Neuropsychopharmacol. 2006 Jul; 9(Suppl 1):S118.
Longo C, Raskin J, Gilsenan AW, Corey-Lisle P, Hopkins JS, Sherrill BH. Prevalence of treatment-resistant depression in Saskatchewan - limitations of a claims-based analysis. Int J Neuropsychopharmacol. 2002 Jun 1;5(Suppl 1):S141. doi: 10.1017/S1461145702003176
Neville C, Whalley D, McKenna SP, Le Comte M, Fortin PR. Adaptation and validation of the Rheumatoid Arthritis Quality of Life Scale for use in Canada. J Rheumatol. 2001 Jul 1;28(7):1505-10.
Perez-Gutthann S, Petri M, Hochberg MC. Comparison of two methods of classifying patients with systemic lupus erythematosus. J Rheumatol. 1991 Aug 1;18(8):1176-9.